相关实验视频

Updated: May 29, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

细胞模型用于测试针对人类PD-L1的药物

O A Shashkova¹, L A Terekhina², I S Malakhov³

¹PhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.

Sovremennye tekhnologii v meditsine

|February 3, 2025

概括

一种新的细胞模型CT26-PD-L1被开发用于测试抗人类PD-L1剂. 该模型有效地评估了治疗和诊断剂在体外和体内环境中的特异性.

科学领域:

生物技术是生物技术.
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

在癌症治疗中,针对编程死亡连接体1 (PD-L1) 的向疗法的开发至关重要.
评估抗PD-L1剂的现有模型需要复杂的基础设施或缺乏全面的测试能力.

研究的目的:

创建和验证一种基因工程细胞模型,用于评估抗人类PD-L1治疗和诊断剂的特异性.
建立一个强大的平台,用于体外和体内对PD-L1向剂的评估.

主要方法:

基因改造的小鼠CT26癌细胞 (CT26-PD-L1) 被创建以表达人类PD-L1.
使用实时PCR和流细胞计证实了PD-L1表达.
该模型使用放射性同位素结合抗PD-L1纳米体进行了体外和体内特异性和内化研究的测试.

主要成果:

CT26-PD-L1细胞系成功地表达了人类的PD-L1,并在小鼠中形成了瘤.
在体内研究表明CT26-PD-L1瘤中放射性免疫结合物的特定积累,但在对照CT26瘤中没有.
在体外实验证实了CT26-PD-L1细胞对抗PD-L1纳米体的内部化.

结论:

开发的CT26-PD-L1细胞模型适用于体外和体内对抗人类PD-L1剂特异性的测试.
该模型为新型PD-L1向治疗和诊断的临床前评估提供了有价值的工具.
该模型有助于在单个试验中确认药物特异性和量化标结合分数.

关键词:

CT26 CT26 在线观看在PD-L1中.这就是VHH VHH.细胞模型细胞模型无线电连合物是一种无线电连合物.有针对性的代理商.瘤模型瘤模型

更多相关视频

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...